Amicus Therapeutics, Inc. (FOLD) reported fourth-quarter 2023 adjusted earnings of 1 cent per share against the Zacks Consensus Estimate of a loss of 6 cents. The company had reported a loss of 17 cents per share in the year-ago quarter.The year-over-year improvement can be attributed to higher revenues of Galafold (migalastat) and the successful ongoing commercial launch of the newly approved Pombiliti + Opfolda.Revenues in the fourth quarter totaled $115.1 million, up 31% year over year on a reported basi ...

Olivier Le Moal Shares of Amicus Therapeutics (NASDAQ:FOLD) are up modestly since my September 2023 update where I argued that the limited label of Pombiliti+Opfolda may not matter for the product combination's uptake because it would have been used like the label says anyway. And while there are no real pipeline updates to look forward to, the company may attract a different kind of investor base going forward - investors predominantly focused on revenue and earnings momentum. Amicus should start deliverin ...

Amicus Therapeutics, Inc. (NASDAQ:FOLD) Q4 2023 Earnings Conference Call February 28, 2024 8:30 AM ET Company Participants Andrew Faughnan - Vice President, Investor Relations Bradley Campbell - President & Chief Executive Officer Sebastien Martel - Chief Business Officer Jeff Castelli - Chief Development Officer Simon Harford - Chief Financial Officer Conference Call Participants Malcolm Kuno - JPMorgan Ritu Baral - TD Cowen Dae Gon Ha - Stifel Joseph Schwartz - Leerink Partners Ellie Merle - UBS Jeff Hung ...

This presentation contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 relating to preclinical and clinical development of our product candidates, the timing and reporting of results from preclinical studies and clinical trials, the prospects and timing of the potential regulatory approval of our product candidates, commercialization plans, manufacturing and supply plans, financing plans, and the projected revenues and cash position for the Company ...

Amicus Therapeutics (FOLD) came out with a quarterly loss of $0.11 per share versus the Zacks Consensus Estimate of a loss of $0.06. This compares to loss of $0.19 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -83.33%. A quarter ago, it was expected that this pharmaceutical company would post a loss of $0.08 per share when it actually produced a loss of $0.07, delivering a surprise of 12.50%.Over the last four quarters, the ...

2023 Total Revenue of $399.4M, a 21% Increase Year-over-Year Strong Patient Demand Continues for Pombiliti™ + Opfolda™ in the U.S., U.K., and Germany Projecting 2024 Galafold® Revenue Growth of 11-16% at CER Anticipating Full-Year Non-GAAP Profitability in 2024 Conference Call and Webcast Today at 8:30 a.m. ET PRINCETON, N.J., Feb. 28, 2024 (GLOBE NEWSWIRE) -- Amicus Therapeutics (NASDAQ:FOLD), a patient-dedicated global biotechnology company focused on developing and commercializing novel medicines for rar ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-33497 Amicus Therapeutics, Inc. (Exact Name of Registrant as Specified in Its Charter) Delaware 71-0869350 (State or Other Jurisdicti ...

Amicus Therapeutics Inc. (NASDAQ:FOLD) Q3 2023 Earnings Conference Call November 8, 2023 8:30 AM ET Company Participants Andrew Faughnan - Vice President, Investor Relations Bradley Campbell - President, Chief Executive Officer Sebastien Martel - Chief Business Officer Simon Harford - Chief Financial Officer Jeff Castelli - Chief Development Officer Mitchell Goldman - Chief Medical Officer Ellen Rosenberg - Chief Legal Officer Mike Kaveney - President of U.S. Commercial Business and Head of Global Marketing ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-33497 Amicus Therapeutics, Inc. (Exact Name of Registrant as Specified in Its Charter) Delaware 71-0869350 (State or Other J ...

Amicus Therapeutics Inc. (NASDAQ:FOLD) Q2 2023 Results Conference Call August 8, 2023 8:30 AM ET Company Participants Andrew Faughnan - Vice President, Investor Relations Bradley Campbell - President, Chief Executive Officer Daphne Quimi - Chief Financial Officer Sébastien Martel - Chief Business Officer Jeff Castelli - Chief Development Officer Mitchell Goldman - Chief Medical Officer Ellen Rosenberg - Chief Legal Officer Conference Call Participants Tazeen Ahmad - Bank of America Anupam Rama - JPMorgan Ri ...